Atherosclerosis quantification by ultrasound Henrik Sillesen MD, DMSc Chairman & professor Dept. Vascular Surgery, Rigshospitalet Univ. of Copenhagen,

Slides:



Advertisements
Similar presentations
1 CAMELOT: Study Design A Morbidity and Mortality Study Patients with documented CAD on standard-of-care therapies* (n=1997) Clinical events (morbidity.
Advertisements

Tasneem Z Naqvi, MD, FRCP (UK), RVT, MMM Director Non-invasive Cardiology and Echocardiography Professor of Medicine and Clinical Scholar Keck School of.
New concepts and guidelines in the management of LDL-c and CV Risk: Need for early intervention Prof. Ulf Landmesser University Hospital Zürich Switzerland.
The INSIGHT study - Reliable blood pressure control and additional benefits for hypertensive patients Anthony M Heagerty Department of Medicine Manchester.
Presenter Disclosure Information Diane Bild, MD, MPH Screening for Subclinical Atherosclerosis as a Strategy for CVD Prevention FINANCIAL DISCLOSURE: None.
Prevalence (%) Prevalence of CAC by Degree of cPB No Carotid Plaque cPB Tertile 1 cPB Tertile 2 cPB Tertile 3 (n=1,316) (n=1,498) (n=1,497) (n=1,497) Supplementary.
Efficacy and safety of angiotensin receptor blockers: a meta-analysis of randomized trials Elgendy IY et al. Am J Hypertens. 2014; doi:10,1093/ajh/hpu209.
Long-term predictive value of assessment of coronary atherosclerosis by contrast- enhanced coronary computed tomography angiography: meta- analysis and.
Coronary Calcium Scoring for Risk Stratification and Guidelines Matthew Budoff, MD, FACC, FAHA Professor of Medicine Director, Cardiac CT Harbor-UCLA Medical.
Surrogate Measures of Atherosclerosis and Implications for Evaluating Cardiovascular Risk Nathan D. Wong, Ph.D., F.A.C.C. Associate Professor and Director.
Carotid Intima-Media Thickness (CIMT): A Reproducibility Study Mindy Columbus, Brian Wagner, Emma Barinas-Mitchell Department of Epidemiology, University.
VBWG IDEAL: The Incremental Decrease in End Points Through Aggressive Lipid Lowering Study.
Simvastatin in Patients With Prior Cerebrovascular Disease: HPS
HYPERLIPIDAEMIA. 4S 4444 patients –Hx angina or MI –Cholesterol Simvastatin 20mg (10-40) vs. placebo FU 5 years  total cholesterol 25%;  LDL.
COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)
Clinical Outcomes with Newer Antihyperglycemic Agents
Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Trial MEGA Trial Presented at The American Heart Association.
Prasugrel vs. Clopidogrel for Acute Coronary Syndromes Patients Managed without Revascularization — the TRILOGY ACS trial On behalf of the TRILOGY ACS.
Calculated LDL by Age Cases vs. Controls Figure 1.
Monitoring CAC and IMT: A useful clinical tool? Cardiology Service Walter Reed Army Medical Center Walter Reed Army Health Care System NO CONFLICTS TO.
Laura Mucci, Pharm.D. Candidate Mercer University 2012 Preceptor: Dr. Rahimi February 2012.
1 INTIMA MEDIA THICKNESS AND ATHEROSCLEROSIS Michele CAZAUBON, MD, PhD American Hospital of Paris ( France)
WOSCOPS: West Of Scotland Coronary Prevention Study Purpose To determine whether pravastatin reduces combined incidence of nonfatal MI and death due to.
Monocyte damaged endothelium macrophage foam cell lipid thrombocytes plaque oxidative stress smooth muscle cells 4 5 Gaviraghi et al., 1998 Lacidipine:
Published in Circulation 2003 Rory Hachamovitch, MD, MSc; Sean W. Hayes, MD; John D. Friedman, MD; Ishac Cohen PhD; Daniel S. Berman, MD Comparison of.
Predictive Value of Coronary Calcium Scoring Matthew Budoff, MD, FACC, FAHA Associate Professor of Medicine UCLA School of Medicine Director, Cardiac CT.
Clinical Trial Results. org SAGE Trial Prakash Deedwania, MD; Peter H. Stone, MD; C. Noel Bairey Merz, MD; Juan Cosin-Aguilar, MD; Nevres Koylan, MD; Don.
1 Part 1 Importance of Identifying and Managing Postprandial Hyperglycemia An Educational Service from G LYCO M ARK G LYCO M ARK is a registered trademark.
Hypothesis Evaluated in these Papers
Coronary Artery Calcium
Age-standardized mortality from ischaemic heart disease in European regions (men; age group years; year 2000) J Muller-Nordhorn, et al. Eur Heart.
4S: Scandinavian Simvastatin Survival Study
Clinical Outcomes with Newer Antihyperglycemic Agents FDA-Mandated CV Safety Trials 1.
Clinical Trial Results. org METEOR Trial Presented at the American College of Cardiology Annual Scientific Session March, 2007 Presented by Dr. John R.
CHD Prevention in the Elderly: Should All Older Adults Be Treated? Lew Kuller, Dr.P.H., M.D., Graduate School of Public Health Professor, Department of.
CAPRICORN Adverse CV Events (Frequency ≥ 1.5%) in Either Treatment Group (Uptitration Phase)
Rosuvastatin 10 mg n=2514 Placebo n= to 4 weeks Randomization 6weeks3 monthly Closing date 20 May 2007 Eligibility Optimal HF treatment instituted.
Peripheral Artery Disease in Orthopaedic Patients with Asymptomatic Popliteal Artery Calcification on Plain X-ray Adam Podet, MS; Julia Volaufova, phD,;
Date of download: 6/1/2016 Copyright © The American College of Cardiology. All rights reserved. From: Carotid Intima-Media Thickness and Plaque in Cardiovascular.
Are We There Yet ? Abdul H. Sankari, MD FACC FCCP.
Ten Year Outcome of Coronary Artery Bypass Graft Surgery Versus Medical Therapy in Patients with Ischemic Cardiomyopathy Results of the Surgical Treatment.
Trends in Hospitalizations and Outcomes for Acute Cardiovascular Disease and Stroke, 1999–2011CLINICAL PERSPECTIVE by Harlan M. Krumholz, Sharon-Lise T.
Prof. Dr. Sigmund Silber, FESC, FACC On behalf of the RESOLUTE
LEADER trial: Primary Outcome
Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies  The Emerging.
Clinical need for determination of vulnerable plaques
The Role of Cardiac CT in Women
Insights from the NCDR® STS/ACC TVT Registry.
CANTOS: The Canakinumab Anti-Inflammatory Thrombosis Outcomes Study
SPIRE Program: Studies of PCSK9 Inhibition and the Reduction of Vascular Events Unanticipated attenuation of LDL-c lowering response to humanized PCSK9.
American College of Cardiology Presented by Dr. Stephan Windecker
Coronary Revascularization and TAVR
Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies  The Emerging.
Major carotid plaque surface irregularities correlate with neurologic symptoms  Aaron Troyer, BA,, David Saloner, PhD,, Xian Mang Pan, MD,, Pauline Velez,
Long-term incidence of myocardial infarct, stroke, and mortality in patients operated on for abdominal aortic aneurysms  Nikolaj Eldrup, MD, PhD, Jacob.
Prospective evaluation of the relationship between C-reactive protein, D-dimer and progression of peripheral arterial disease  Scott E. Musicant, MD,
Axial source images of left severe ICA stenosis; small residual lumen with vessel wall plaque and thick calcification on the sides. Axial source images.
Large-Scale Registry Examining Safety and Effectiveness of Zotarolimus-Eluting and Sirolimus-Eluting Stents in Patients with Coronary Artery Disease Western.
Potential mechanisms whereby statins may reduce the risk of stroke
B-mode ultrasound measurement of the distance between the line indicated by Arrow 1 (lumen-intima interface) and the line marked by Arrow 2 (media-adventitia.
Correlation between endothelial function and hypertension
Distribution of Cardiovascular Risk Factors by Baseline CRP Concentration M. Cushman et al. Circulation. 2005;112:25-31.
Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies  The Emerging.
Simvastatin in Patients With Prior Cerebrovascular Disease: HPS
SPIRE Program: Studies of PCSK9 Inhibition and the Reduction of Vascular Events Unanticipated attenuation of LDL-c lowering response to humanized PCSK9.
Volume 75, Issue 1, Pages (January 2009)
EMPA-REG OUTCOME: Cumulative incidence of the primary outcome
Additional benefit of PCSK9 inhibition in high risk patients after myocardial infarction A FOURIER subanalysis Primary endpoint: composite of CV death,
The benefit of evolocumab treatment is consistent regardless of inflammation level HR %CI ARR 1.6% 1.8%
Cardiac death, target vessel myocardial infarction (MI), target lesion revascularisation (TLR) by Kaplan-Meier method. Cardiac death, target vessel myocardial.
Presentation transcript:

Atherosclerosis quantification by ultrasound Henrik Sillesen MD, DMSc Chairman & professor Dept. Vascular Surgery, Rigshospitalet Univ. of Copenhagen, Denmark Henrik Sillesen MD, DMSc Chairman & professor Dept. Vascular Surgery, Rigshospitalet Univ. of Copenhagen, Denmark

What should we look at? Intima-media thickness Plaque

CAPS-study 10-year results

Conclusion: Despite cIMT being predictive for cardiovascular endpoints, it did not consistently improve the risk classification of individuals Lorenz et al, Eur Heart J 2010

Transducer

Why IMT is irrelevant for the individual person

Plaque imaging IS relevant Small plaque Larger plaque

Assessment of plaque Plaque Presence Plaque Presence Plaque quantification Plaque quantification Plaque area Plaque area Degree of stenosis Degree of stenosis Plaque burden Plaque burden Plaque volume Plaque volume Plaque Presence Plaque Presence Plaque quantification Plaque quantification Plaque area Plaque area Degree of stenosis Degree of stenosis Plaque burden Plaque burden Plaque volume Plaque volume

PLAQUE PRESENCE

Plaque definition Well defined (consensus) in Europe and US: Well defined (consensus) in Europe and US: Localized thickening of 50% or greater compared to surrounding vessel wall Localized thickening of 50% or greater compared to surrounding vessel wall Protrusion into lumen 0.5 mm or greater Protrusion into lumen 0.5 mm or greater IMT > 1,5 mm IMT > 1,5 mm Consensus statement from the American Society of Echocardiography Carotid Intima-Media Thickness Task Force. J Am Soc Echocardiogr 2008; 21:93–111 Toubul PJ, Hennerici MG, Meairs S. Mannheim carotid intima media thickness consensus Cerebrovasc Dis 2007;23:75– 80. Well defined (consensus) in Europe and US: Well defined (consensus) in Europe and US: Localized thickening of 50% or greater compared to surrounding vessel wall Localized thickening of 50% or greater compared to surrounding vessel wall Protrusion into lumen 0.5 mm or greater Protrusion into lumen 0.5 mm or greater IMT > 1,5 mm IMT > 1,5 mm Consensus statement from the American Society of Echocardiography Carotid Intima-Media Thickness Task Force. J Am Soc Echocardiogr 2008; 21:93–111 Toubul PJ, Hennerici MG, Meairs S. Mannheim carotid intima media thickness consensus Cerebrovasc Dis 2007;23:75– 80.

Polak et al, NEJM 2011 Framingham Off-Spring

Polak et al: JAHE 2013 MESA study Any plaque

Plaque area

Spence et al, stroke 2002

Tromsø Study Johnsen et al. Stroke 2007 Plaque area and risk of MI – men and women

Plaque Burden

BioImage Study Muntendam et al: Am Heart J 2010;160:49-57

HRP introduced the ”cross sectional sweep”

“Manual 3D” Cross-sectional Carotid Sweep Sillesen et al., JACC Img 2012 Area of all carotid plaques was summed yielding a continuous metric of total carotid atherosclerosis: carotid plaque burden (cPB)

CAC groups vs ”plaque burden” and IMT Spearman: 0.194Spearman: P < 0.01 IMT Plaque ”burden”

Analysis time, Days Cumulative MACE by Carotid Plaque Burden No PlaqueTertile 1 Tertile 2Tertile cPB Tertile cPB Tertile cPB Tertile cPB= 0 Number at risk Cumulative Incidence, % p-value<.0001

Adjusted Hazard ratios for MACE (all-cause mortality) Conventional vascular risk factors Unadjusted Categories of CAC score Age and sex adjusted > (3.39, 7.72) 1.86 (1.17, 2.95) 1.58 (0.91, 2.73) 1.79 (1.13, 2.85) 1.53 (0.97, 2.43) 2.28 (1.37, 3.81) 3.55 (2.28, 5.54) 1.40 (0.88, 2.22) 2.98 (1.81, 4.93) 2.21 (1.41, 3.47) 3.28 (2.00, 5.38) 2.23 (1.33, 3.73) 2.61 (1.57, 4.34) 1.65 (0.96, 2.85) ratio (95% CI) 1.36 (0.86, 2.17) 4.21 (2.60, 6.82) 3.89 (2.50, 6.06) 1.59 (0.92, 2.75) Hazard < P for trend < (1.33, 3.73) Hazard ratio vs. no detectable plaque / CAC Top third Bottom third Middle third Top third Bottom third Middle third Top third Bottom third Middle third > > Conventional vascular risk factors Unadjusted Age and sex adjusted Unadjusted and adjusted hazard ratios for MACE (all-cause death, myocardial infarction, ischemic stroke, unstable angina or coronary revascularization) associated with CAC (top panel) and cPB (bottom panel) Thirds of detectable Carotid Plaque Burden

Net Reclassification Index for MACE Proportion Correctly Reclassified, % (n=3899) (n=1613) (n=296)

Plaque Volume by 3D US Now possible – great potential However, no trials done yet so the true value is unknown.

Combined carotid plaque and CAC JACC 2015:

Atherosclerosis 2001

Value of ultrasound in risk prediction for the individual IMT: DOES NOT WORK IMT: DOES NOT WORK Plaque presence: doubles risk Plaque presence: doubles risk Plaque area, degree of stenosis, plaque thickness and 2D plaque burden all discriminate better – plaque burden best Plaque area, degree of stenosis, plaque thickness and 2D plaque burden all discriminate better – plaque burden best Power of ”zero plaque” seems equal to that of CACS = 0 Power of ”zero plaque” seems equal to that of CACS = 0 Maybe better to evaluate more than 1 location Maybe better to evaluate more than 1 location IMT: DOES NOT WORK IMT: DOES NOT WORK Plaque presence: doubles risk Plaque presence: doubles risk Plaque area, degree of stenosis, plaque thickness and 2D plaque burden all discriminate better – plaque burden best Plaque area, degree of stenosis, plaque thickness and 2D plaque burden all discriminate better – plaque burden best Power of ”zero plaque” seems equal to that of CACS = 0 Power of ”zero plaque” seems equal to that of CACS = 0 Maybe better to evaluate more than 1 location Maybe better to evaluate more than 1 location